Laurus Labs invests ₹107.8 crore in joint venture KRKA Pharma through a rights issue, keeping its 49% stake
- Mergers & acquisitions
- Pharmaceuticals
Laurus Labs Limited has told the exchanges that it has invested ₹107.8 crore (₹1,078,000,000) in KRKA Pharma Private Limited, a joint venture between KRKA d.d., Novo mesto, Slovenia, and Laurus Labs. The company bought 10,78,00,000 equity shares of KRKA Pharma with a face value of ₹10 each, at face value, through a rights issue.
The disclosure was made on 14 Oct 2026 and continues the company’s intimation of 30 Apr 2026 about the further investment. After the investment, Laurus Labs holds 26,21,50,000 equity shares of KRKA Pharma, and its percentage holding stays at 49%.
Inference
Because the shares were bought through a rights issue and the holding stayed at 49%, the investment adds to the joint venture’s capital without changing the ownership split between the two partners.
The filing does not say what the money will be used for. The company’s earlier intimation of 30 Apr 2026 is where the plan was first described.
Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
